Quantitative thyroid scintigraphy for the differentiation of Graves' disease and hyperthyroid autoimmune thyroiditis

NuklearMedizin

Volumn 43, Issue 4, 2004, Pages 124-128

  Sahlmann, C O ^a   Siefker, U ^a   Lehmann, K ^a   Harms, E ^a   Conrad, M ^a   Meller, Johannes ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Autoimmune thyroiditis; Graves disease; Pertechnetate; Sodium iodide symporter; Thyroid scintigraphy; TSH receptor antibodies

Indexed keywords

PERTECHNETIC ACID TC 99M; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPOTHYROIDISM; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; THYROID SCINTISCANNING; THYROID WEIGHT; TREATMENT OUTCOME;

EID: 4344617717     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625315     Document Type: Article

References (24)

1. Ajjan RA, Kemp EH, Waterman EA et al. Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 2000; 85: 2020-7.
2. Bähre M, Hilgers R, Lindemann C et al. Thyroid autonomy: sensitive detection and estimation of its functional relevance using quantified high-resolution scintigraphy. Acta Endocrinol (Copenh) 1988; 117: 145-53.
3. Becker W, Wolf F. Thyroid scintigraphy: Tc-99m-pertechnetate and I-123. Exp Clin Endocrinol 1994; 102 (Suppl. 3): 1-11.
4. Bolton J, Sanders J, Sanders J et al. Measurements of thyroid-stimulating hormone receptor-autoantibodies by ELISA. Clin Chem 1999; 45: 2285-7.
5. Caillou B, Troalen F, Baudin E et al. Na+/I-symporter distribution in human thyroid tissues: An immunohistological study. J Clin Endocrinol Metab 1998; 83: 4102-6.
6. Castagliola S, Morgenthaler NG, Hoermann R et al. Second generation assay for thyrotropin receptor antibodies has superior sensitivity for Graves' disease. J Clin Endocrinol Metab 1999; 84: 90-7.
7. Castro MR, Bergert ER, Beito TG et al. Development of monoclonal antibodies against the human sodium iodine symporter: Immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 1999; 84: 2957-62.
8. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodine transporter. Nature 1996; 379: 458-60.
9. Emrich D, Erlenmaier U, Pohl M et al. Determination of the autonomously functioning volume of the thyroid. Eur J Nucl Med 1993; 20: 410-4.
10. Endo T, Kaneshige M, Nakazato M et al. Autoantibody against iodine transporter in sera of patients with Hashimoto's thyroiditis possesses iodine transport inhibitory activity. Biochem Bioph Res Com 1996; 228: 199-202.
11. - symporter: mechanisms, stoichiometry, and specifity. J Biol Chem 1997; 272: 27230-8.
12. Joba W, Spitzweg C, Schriever K et al. Analysis of human sodium/iodide symporter, thyroid transcription factor-1, and paired-box-protein-8 gene expression in benign thyroid diseases. Thyroid 1999; 9: 455-66.
13. Joseph K. Statische, dynamische und quantifizierte Schilddrü senszintigraphie. Nuklearmediziner 1979; 2: 83-101.
14. Lacey NA, Jones A, Clarke SE. Role of radionuclide imaging in hyperthyroid patients with no clinical suspicion of nodules. Br J Radiol 2001; 74: 486-9.
15. 99mTc- Speichertestes als Schätzer der thyroidalen Stimulation. Fortschr Röntgenstr 1979; 131: 536-44.
16. Mariano M, Latrofa F, Barbesino G et al. Pathogenetic and clinical aspects of autoimmune thyroiditis. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl 3): S79-83.
17. Meller J, Schreivogel I, Bergmann A et al. Klinische Implikationen eines neuen TSH-Rezeptor-Antikörper-Assays (DYNOtest® TRAKhuman) bei autoimmunen Schilddrüsenerkrankungen. Nuklearmedizin 2000; 39: 14-8.
18. Meller J, Jauho A, Hüfner M et al. Disseminated thyroid autonomy versus Graves disease: Reevaluation by a second generation TSH-receptor-antibody assay. Thyroid 2000; 10: 1085-91.
19. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging 2002; 29 (Suppl 2): S486-91.
20. - symporter messenger ribonucleic acid levels in FRTL-5 cells. Endocrinology 1998; 139: 703-12.
21. 99mTc- pertechnetate for measuring thyroid-suppressibility. J Nucl Med 1971; 12: 51-4.
22. Spitzweg C, Joba W, Morris JC et al. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 1999; 9: 821-30.
23. Yarman S, Mudun A, Alagol F et al. Scintigraphic varieties in Hashimoto's thyroiditis and comparison with ultrasonography. Nucl Med Commun 1997; 18: 951-6.
24. Zophel K, Wunderlich G, Kopprasch C et al. Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease. Nuklearmedizin 2003; 42: 63-70.